Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 65862-626

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 65862-626). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

The image shows a plot of the estimated probability of achieving an initial headache response by two hours in pooled studies 1, 2, 3, and 4. The plot displays the probability over time of obtaining headache response following treatment with rizatriptan benzoate or placebo. The averages displayed are based on pooled data from four placebo-controlled, outpatient trials providing evidence of efficacy. Patients taking additional treatment or not achieving headache response prior to 2 hours were censored at 2 hours.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

The image shows a graph representing the estimated probability of patients taking a second dose of Rizatriptan Benzoate Tablets or other medication for migraines over 24 hours following the initial dose of study treatment in pooled studies 1, 2, 3, and 4. The graph is a Kaplan-Meier plot based on data obtained in 4 placebo-controlled outpatient clinical trials. Patients who did not use additional treatments were censored at 24 hours. The plot includes both patients who had a headache response at 2 hours and those who did not have a response to the initial dose. Remedication was not allowed within 2 hours post-dose.*

FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Not available.*

FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)

The text describes a figure showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate orally disintegrating tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled studies 5 and 6. The plot is based on data obtained in two placebo-controlled outpatient clinical trials (Studies 3 and 6), and patients not using additional treatments were censored at 24 hours. The plot includes both patients who had a headache response at 2 hours and those who did not. However, the text contains some errors, including misread characters and missing words.*

FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

The text describes a figure (Figure 5) that shows the percentage of patients reporting no headache pain after 2 hours of taking Rizatriptan Benzoate 0D tablets or a placebo. The figure includes a graph with percentage values ranging from 0% to 100% (in increments of 10%). The x-axis shows "Hours Post Stage 2 Dose," with values ranging from 0 to 20. The y-axis indicates the percentage of patients without headache pain.*

FDA Label Image

Package Label-principal Display Panel (5 mg Unit-of-Use Pack (9 Tablets))

FDA Label Image

Package Label-principal Display Panel (10 mg Unit-of-Use Pack (9 Tablets))

This is a description of a medication called Rizatriptan Benzoate. It comes in the form of orally disintegrating tablets that have been distributed by NDG with a code of 65862-625-36. Each tablet has 5mg of rizatriptan benzoate which is equivalent to rizatriptan. The manufacturer is Aurobindo Pharma USA, Inc. The tablets contain a component of aspartame called eiewweionrcs cotanspreyianne at a quantity of 1.05mg per code TS/DRUGS/22/2009. The medication is to be stored at a controlled room temperature between 20 to 25 degrees Celsius. The usual adult dosage is not available.*

FDA Label Image

Rizatriptan Fig8

FDA Label Image

Rizatriptan Fig9

This text describes a medication named Rizatriplan Benznate and provides the equivalent dosage of 10 mg. It also mentions the manufacturer called Aot Poarma USA, specifically their location at Princeton-Hightstown Road East Windsor, NJ 08520. The medication is an orally disintegrating tablet and contains phenylalanine, which is a component of aspartame. The recommended adult dosage information is provided in an accompanying circular. The medication should be stored at a controlled room temperature of 20° to 25°C (68° to 77°F). Overall, this text provides important information for individuals who may be taking this medication.*

FDA Label Image

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.